Moms On Mushrooms empowering a community of moms to learn about the value of building a relationship with mushrooms and to support each other in their microdosing journeys.
In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
In our conversation, Sa’ad gives us an overview of how his interest in philosophy led to his involvement with plant medicine, how the psychedelic industry is currently misunderstood and under appreciated, Noetic’s portfolio selection process, and more!
This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.
This week in psychedelic business: Mindset Pharma’s new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”
This week in psychedelic business news: NeonMind’s Medical Advisory Board, Mynd’s public listing, and a new study supports novel use of DMT.
This week in psychedelic business news: Therapists cleared to try…
This week in psychedelic business news: Therapeutic uses of salvinorin A, a 5-MeO-DMT retreat, and World Boxing Council explores psychedelics.
This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.
This week in psychedelic business news: Atai to raise $100 million, Silo’s psilocybin nasal spray, and more.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.